Use of Continuous Glucose Monitoring Indicators to Guide Dose Titration of Weekly Basal Insulin Efsitora Alfa in Insulin-Naive and Basal Insulin-Experienced Adults with Type 2 Diabetes: A Retrospective Analyis

{"INTRODUCTION:":[0],"Basal":[1],"insulin":[2,41,82,282],"dose":[3,83,110,205,214,240],"titration":[4,45,102,111,241,257],"has":[5],"historically":[6],"relied":[7],"on":[8,281],"fasting":[9,62,76,93,119,187,195,235],"self-monitoring":[10,61,248],"blood":[11],"glucose":[12,35,64,167,236],"(SMBG)":[13],"and":[14,23,48,66,70,78,113,121,139,184,193,222,234,247,265],"hypoglycemic":[15,68,134,180,245],"events.":[16],"This":[17],"retrospective":[18],"analysis":[19],"of":[20,33,81,191,213,232,255],"the":[21,31,105,143],"QWINT-2":[22,183],"QWINT-3":[24],"Phase":[25,107,145],"3":[26,108,146],"trials":[27],"aimed":[28],"to":[29,259],"evaluate":[30],"use":[32,276],"continuous":[34],"monitoring":[36],"(CGM)-derived":[37],"indicators":[38,77,94,126,174,188,231],"for":[39,130,211,216,274],"weekly":[40,100,129,209,228],"efsitora":[42],"alfa":[43],"(efsitora)":[44],"in":[46,164,182,263,277],"insulin-naive":[47,221,264],"basal":[49,223,266],"insulin-experienced":[50,224,267],"adults":[51,268,278],"with":[52,60,97,132,154,178,202,204,227,269,272,279],"type":[53],"2":[54],"diabetes":[55,280],"(T2D)":[56],"through":[57,99],"dose-to-dose":[58,101],"comparisons":[59],"plasma":[63],"(FPG)":[65],"CGM-derived":[67,133,179,244],"events,":[69],"by":[71,114],"assessing":[72,115],"concordance":[73,116],"between":[74,117],"CGM":[75,92,118,124,159,172,186,230,275],"FPG":[79,98,122],"independent":[80],"adjustment.":[84],"METHODS:":[85],"=":[86],"655)":[87],"efsitora-treated":[88],"participants":[89],"were":[90,95,127],"analyzed.":[91],"compared":[96],"decisions":[103,215,242],"following":[104,142],"SMBG-based":[106,144],"trial":[109,147],"algorithm,":[112],"indicator":[120,160],"values.":[123],"hypoglycemia":[125,148,173,233],"assessed":[128],"agreement":[131,177],"events":[135,181,246],"below":[136],"70":[137],"mg/dL":[138,141],"54":[140],"criteria.":[149],"User":[150],"burden":[151,156],"was":[152,161],"considered,":[153],"low":[155],"meaning":[157],"a":[158,260],"readily":[162],"available":[163],"an":[165],"ambulatory":[166],"profile":[168],"(AGP)":[169],"report.":[170],"RESULTS:":[171],"demonstrated":[175,199],"91.5%-98.3%":[176],"QWINT-3.":[185],"\\"Lowest":[189],"median":[190],"AGP,\\"":[192],"\\"Typical":[194],"25%":[196],"from":[197],"AGP\\"":[198],"clinical":[200],"equivalency":[201],"FPG,":[203,249],"differences":[206],"within":[207],"20":[208],"units":[210],"90.7%-93.4%":[212],"both":[217],"studies.":[218],"CONCLUSION:":[219],"In":[220],"populations":[225],"treated":[226],"efsitora,":[229],"yielded":[237],"clinically":[238],"equivalent":[239],"as":[243],"respectively.":[250],"These":[251],"findings":[252],"support":[253],"translation":[254],"established":[256],"practices":[258],"CGM-based":[261],"workflow":[262],"T2D,":[270],"consistent":[271],"recommendations":[273],"therapy.":[283]}